Literature DB >> 6613839

Relationships between amiodarone dosage, drug concentrations, and adverse side effects.

J J Heger, E N Prystowsky, D P Zipes.   

Abstract

The relationships between size of loading dose and drug concentration, size of maintenance dose and drug concentration, and pulmonary and cutaneous adverse side effects and drug dosage were examined in patients given amiodarone. Amiodarone and metabolite concentrations in plasma and red cell samples were measured by specific high-pressure liquid chromatography. During drug loading, a daily dose schedule of 1600 mg/day produced significantly higher drug concentrations than did a loading dose schedule of 800 mg/day. During maintenance therapy, amiodarone dosage correlated with drug concentrations but with a wide interpatient variability for any given dosage level. The ratio of desethylamiodarone to amiodarone remained relatively constant over different dosage or drug concentration ranges, but increased with duration of treatment, suggesting a time-dependent metabolic function that may be analogous to the time-dependent attainment of maximal antiarrhythmic effect. The occurrence of pulmonary toxicity from amiodarone was not related to duration of treatment or cumulative dose of drug, buy may relate to the magnitude of the maintenance dose of amiodarone. Blue skin discoloration occurred in 19 (36%) of 53 patients receiving amiodarone for longer than 17 months, and may relate to the cumulative dose.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6613839     DOI: 10.1016/0002-8703(83)90018-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  17 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Stability of plasma amiodarone levels during chronic oral therapy.

Authors:  K Robinson; A Johnston; S Walker; J Mulrow; D Holt; W McKenna
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

3.  P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms.

Authors:  Matthew G McDonald; Nicholas T Au; Allan E Rettie
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

Review 4.  Recent advances in understanding the pharmacology of amiodarone.

Authors:  S Nattel; M Talajic
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

5.  Tremor: a possible side effect of prolonged therapy with low doses of amiodarone.

Authors:  S Della Sala; C Marchetti
Journal:  Ital J Neurol Sci       Date:  1989-04

Review 6.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

8.  Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.

Authors:  M E Veronese; S McLean; R Hendriks
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

9.  [Amiodarone-induced pneumonitis. Lethal complication in a patient after thoracic surgery].

Authors:  V Ghezel-Ahmadi; V C Kürschner; A Fisseler-Eckhoff; J Schirren; J E Schmitz; T Obenhaus
Journal:  Anaesthesist       Date:  2008-10       Impact factor: 1.041

10.  Myopathy during amiodarone treatment: a case report.

Authors:  F Carella; E Riva; L Morandi; E Cappiello; A Mangoni
Journal:  Ital J Neurol Sci       Date:  1987-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.